These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 2064730)

  • 1. Circadian secretion pattern of melatonin in Parkinson's disease.
    Fertl E; Auff E; Doppelbauer A; Waldhauser F
    J Neural Transm Park Dis Dement Sect; 1991; 3(1):41-7. PubMed ID: 2064730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease.
    Videnovic A; Noble C; Reid KJ; Peng J; Turek FW; Marconi A; Rademaker AW; Simuni T; Zadikoff C; Zee PC
    JAMA Neurol; 2014 Apr; 71(4):463-9. PubMed ID: 24566763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bright light therapy for depression in Parkinson disease: A randomized controlled trial.
    Rutten S; Vriend C; Smit JH; Berendse HW; van Someren EJW; Hoogendoorn AW; Twisk JWR; van der Werf YD; van den Heuvel OA
    Neurology; 2019 Mar; 92(11):e1145-e1156. PubMed ID: 30770426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Melatonin and parkinsonism.
    Shaw KM; Stern GM; Sandler M
    Lancet; 1973 Feb; 1(7797):271. PubMed ID: 4119422
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting sleep and the circadian system as a novel treatment strategy for Parkinson's disease.
    Feigl B; Lewis SJG; Rawashdeh O
    J Neurol; 2024 Mar; 271(3):1483-1491. PubMed ID: 37943299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Effects of Perinatal Exposure to a Glyphosate-Based Herbicide on Melatonin Levels and Oxidative Brain Damage in Adult Male Rats.
    Cattani D; Pierozan P; Zamoner A; Brittebo E; Karlsson O
    Antioxidants (Basel); 2023 Oct; 12(10):. PubMed ID: 37891904
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parkinson's Disease: A Narrative Review on Potential Molecular Mechanisms of Sleep Disturbances, REM Behavior Disorder, and Melatonin.
    Samizadeh MA; Fallah H; Toomarisahzabi M; Rezaei F; Rahimi-Danesh M; Akhondzadeh S; Vaseghi S
    Brain Sci; 2023 Jun; 13(6):. PubMed ID: 37371392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Melatonin Treatment for Sleep Disorders in Parkinson's Disease: A Meta-Analysis and Systematic Review.
    Ma H; Yan J; Sun W; Jiang M; Zhang Y
    Front Aging Neurosci; 2022; 14():784314. PubMed ID: 35185525
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Computational Analysis in a Cohort of Parkinson's Disease Patients and Clock-Modified Colorectal Cancer Cells Reveals Common Expression Alterations in Clock-Regulated Genes.
    Yalçin M; Malhan D; Basti A; Peralta AR; Ferreira JJ; Relógio A
    Cancers (Basel); 2021 Nov; 13(23):. PubMed ID: 34885088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circadian rhythms in neurodegenerative disorders.
    Nassan M; Videnovic A
    Nat Rev Neurol; 2022 Jan; 18(1):7-24. PubMed ID: 34759373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melatonin as a Reducer of Neuro- and Vasculotoxic Oxidative Stress Induced by Homocysteine.
    Karolczak K; Watala C
    Antioxidants (Basel); 2021 Jul; 10(8):. PubMed ID: 34439426
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated Plasma Melatonin Levels Are Correlated With the Non-motor Symptoms in Parkinson's Disease: A Cross-Sectional Study.
    Li L; Zhao Z; Ma J; Zheng J; Huang S; Hu S; Gu Q; Chen S
    Front Neurosci; 2020; 14():505. PubMed ID: 32508583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polychromatic Light Exposure as a Therapeutic in the Treatment and Management of Parkinson's Disease: A Controlled Exploratory Trial.
    Willis GL; Boda J; Freelance CB
    Front Neurol; 2018; 9():741. PubMed ID: 30778331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circadian Dysregulation in Parkinson's Disease.
    Videnovic A; Golombek D
    Neurobiol Sleep Circadian Rhythms; 2017 Jan; 2():53-58. PubMed ID: 28713867
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The implication of neuronimmunoendocrine (NIE) modulatory network in the pathophysiologic process of Parkinson's disease.
    Shen Y; Guo X; Han C; Wan F; Ma K; Guo S; Wang L; Xia Y; Liu L; Lin Z; Huang J; Xiong N; Wang T
    Cell Mol Life Sci; 2017 Oct; 74(20):3741-3768. PubMed ID: 28623510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A New Perspective for Parkinson's Disease: Circadian Rhythm.
    Li S; Wang Y; Wang F; Hu LF; Liu CF
    Neurosci Bull; 2017 Feb; 33(1):62-72. PubMed ID: 27995565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms.
    Mack JM; Schamne MG; Sampaio TB; Pértile RA; Fernandes PA; Markus RP; Prediger RD
    Oxid Med Cell Longev; 2016; 2016():3472032. PubMed ID: 27829983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A double-blind randomized controlled trial to assess the effect of bright light therapy on depression in patients with Parkinson's disease.
    Rutten S; Vriend C; Smit JH; Berendse HW; Hoogendoorn AW; van den Heuvel OA; van der Werf YD
    BMC Psychiatry; 2016 Oct; 16(1):355. PubMed ID: 27769202
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circadian system - A novel diagnostic and therapeutic target in Parkinson's disease?
    Videnovic A; Willis GL
    Mov Disord; 2016 Mar; 31(3):260-9. PubMed ID: 26826022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consequences of Circadian Disruption on Neurologic Health.
    Videnovic A; Zee PC
    Sleep Med Clin; 2015 Dec; 10(4):469-80. PubMed ID: 26568123
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.